Search

Displaying results 5911 - 5920 of 9705 in total
  1. Drug

    Linvoseltamab

    go.drugbank.com/drugs/DB17447
    ApprovedInvestigational

    Continued approval in the U.S. is contingent upon verification of clinical benefit in a confirmatory trial. [L53363] … Linvoseltamab (INN), marketed as Lynozyfic™, is a bispecific human IgG4 monoclonal antibody developed by Regeneron that promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma

  2. Drug

    MK-0482

    go.drugbank.com/drugs/DB17453
    Investigational

    MK-0482 is a novel humanized IgG4 monoclonal antibody targeting the immunoglobulin-like transcript (ILT) 3.

  3. Drug

    RO-7293583

    go.drugbank.com/drugs/DB17455
    Investigational

    RO-7293583 is a TYRP1-Targeting CD3 T-Cell Engager.

  4. Drug

    ETBX-011

    go.drugbank.com/drugs/DB17464
    Investigational

    ETBX-011 is a cancer vaccine used to treat patients with cancers that express carcinoembryonic antigen (CEA).

  5. Drug

    Nanrilkefusp alfa

    go.drugbank.com/drugs/DB17480
    Investigational

    Nanrilkefusp alfa is a human fusion protein consisting of the cytokine interleukin (IL)-15 and the high-affinity binding sushi+ domain of IL-15 receptor alpha (IL-15Ra).

  6. Drug

    BI-765063

    go.drugbank.com/drugs/DB17482
    Investigational

    BI-765063 is a humanized IgG4 monoclonal antibody antagonist of signal regulatory protein α (SIRPα).

  7. Drug

    PF-07799933

    go.drugbank.com/drugs/DB17489
    Investigational

    PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer.

  8. Drug

    CGX-1321

    go.drugbank.com/drugs/DB17491
    Investigational

    CGX-1321 is a porcupine inhibitor that affects Wnt production and can block Wnt downstream signaling.[A257038]

  9. Drug

    Bioymifi

    go.drugbank.com/drugs/DB17493
    Experimental

    Bioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic. … Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent.

  10. Drug

    SB 11285

    go.drugbank.com/drugs/DB17511
    Investigational

    SB 11285 is a second-generation Stimulator of Interferon Genes (STING) agonist.